Evidence map›Paper›PMID 34551140›Full record

ArticleJournal of clinical laboratory analysis2021

Increased serum exosomal long non-coding RNA SNHG15 expression predicts poor prognosis in non-small cell lung cancer.

Pengfei Han, Jia Zhao, Lun Gao

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of clinical laboratory analysis, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed, 1 pooled it
2.3field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 1 synthesis or guideline pooled it, 31 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Review
  4. Review
  5. Review
  6. Review
  7. Article
  8. The therapeutic potential of exosomes in lung cancer.Cellular oncology (Dordrecht, Netherlands) · 2023
    Review
  9. Review
  10. Review
  11. Review
  12. Review
  13. Review
  14. Review
  15. Review
  16. The crucial roles of long noncoding RNA SNHGs in lung cancer.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2022
    Review
  17. Article
  18. Article
  19. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Pengfei HanDepartment of Respiratory and Critical Care Medicine, Baoji People's Hospital, Baoji City, Shaanxi Province, China.
Jia ZhaoDepartment of Respiratory and Critical Care Medicine, Baoji High-tech Hospital, Baoji City, Shaanxi Province, China.
Lun GaoDepartment of Respiratory and Critical Care Medicine, the First Hospital of Yulin City, Yulin City, Shaanxi Province, China.ORCID https://orcid.org/0000-0002-0933-212X
Baoji City Central Hospital · CNYulin University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundCirculating long non-coding RNAs (lncRNAs) are emerging as promising biomarkers for non-small cell lung cancer (NSCLC). This study aimed to detect serum exosomal lncRNA SNHG15 expression in NSCLC and evaluate its potential clinical value.

methodsA total of 238 serum samples were collected from 118 patients with NSCLC, 40 patients with benign pulmonary lesions and 80 healthy volunteers. The expression levels of serum exosomal lncRNA SNHG15 were measured by quantitative real-time polymerase chain reaction (qRT-PCR). Then, the relationship between serum exosomal lncRNA SNHG15 expression and clinical parameters was analyzed.

resultsThe serum exosomal lncRNA SNHG15 expression was markedly higher in NSCLC patients compared to patients with benign pulmonary lesions and normal controls. As expected, serum exosomal lncRNA SNHG15 was greatly decreased after surgery. High serum exosomal lncRNA SNHG15 expression was closely associated with poor differentiation (p=0.035), positive lymph node metastasis (p=0.009) and advanced TNM stage (p<0.001). Receiver operating characteristic (ROC) curve analysis demonstrated that serum exosomal lncRNA SNHG15 well differentiated all stage NSCLC, stage I/II NSCLC patients or stage III/IV NSCLC patients from controls, and the combination of serum exosomal lncRNA SNHG15 and CEA showed an elevated AUC for distinguishing NSCLC from healthy individuals. In univariate and multivariate analyses, serum exosomal lncRNA SNHG15 was confirmed as an independent prognostic predictor for overall survival.

conclusionIn conclusion, our findings suggest that serum exosomal lncRNA SNHG15 might be a potential biomarker for early diagnosis and prognosis prediction of NSCLC.

Indexed as

Carcinoma, Non-Small-Cell LungLung NeoplasmsBiomarkers, TumorExosomesFemaleHumansMaleMiddle AgedPrognosisRNA, Long NoncodingUp-RegulationBiomarkers, TumorRNA, Long NoncodingdiagnosislncRNAnon-small cell lung cancerprognosisSNHG15

Identifiers

PMID34551140
PMCPMC8605147
OpenAlexW3200379058

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.